Lyell Immunopharma, Inc. financial data

Symbol
LYEL on Nasdaq
Industry
Pharmaceutical Preparations
Location
201 Haskins Way, South San Francisco, CA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.64K % -1.13%
Debt-to-equity 14.7 % +2.29%
Return On Equity -33.4 % -26.3%
Return On Assets -29.1 % -26%
Operating Margin -418K % -96517%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 256M shares +1.98%
Common Stock, Shares, Outstanding 256M shares +1.96%
Entity Public Float 654M USD -40.5%
Common Stock, Value, Issued 26K USD +4%
Weighted Average Number of Shares Outstanding, Basic 255M shares +2.08%
Weighted Average Number of Shares Outstanding, Diluted 255M shares +2.08%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 54K USD -99.9%
Research and Development Expense 174M USD +1.48%
General and Administrative Expense 54.4M USD -40%
Operating Income (Loss) -226M USD -7.62%
Nonoperating Income (Expense) 15.4M USD +8357%
Net Income (Loss) Attributable to Parent -210M USD -0.36%
Earnings Per Share, Basic -0.82 USD/shares +2.38%
Earnings Per Share, Diluted -0.82 USD/shares +2.38%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 133M USD -40.5%
Marketable Securities, Current 358M USD -3.68%
Assets, Current 500M USD -17.6%
Property, Plant and Equipment, Net 93.1M USD -18.1%
Operating Lease, Right-of-Use Asset 37.7M USD -9.19%
Other Assets, Noncurrent 4.24M USD -6.22%
Assets 654M USD -21.7%
Accounts Payable, Current 4.2M USD -27.7%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 30.9M USD -10.2%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 53.3M USD -11.5%
Other Liabilities, Noncurrent 3.44M USD -11.5%
Liabilities 87.6M USD -11%
Accumulated Other Comprehensive Income (Loss), Net of Tax -397K USD +83.3%
Retained Earnings (Accumulated Deficit) -1.11B USD -23.4%
Stockholders' Equity Attributable to Parent 567M USD -23.1%
Liabilities and Equity 654M USD -21.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -42M USD +9.08%
Net Cash Provided by (Used in) Financing Activities 27K USD
Net Cash Provided by (Used in) Investing Activities 22M USD -31.6%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 256M shares +1.96%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -20M USD -41.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 134M USD -40.5%
Deferred Tax Assets, Valuation Allowance 248M USD +37.9%
Deferred Tax Assets, Gross 263M USD +33.8%
Operating Lease, Liability 60.2M USD -8.86%
Payments to Acquire Property, Plant, and Equipment 1.53M USD -84.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -208M USD -2.33%
Lessee, Operating Lease, Liability, to be Paid 78M USD -12.5%
Property, Plant and Equipment, Gross 154M USD -0.71%
Operating Lease, Liability, Current 6.9M USD +17.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 12.2M USD +2.95%
Lessee, Operating Lease, Liability, to be Paid, Year One 11.9M USD +4.51%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 17.7M USD -23.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 12.6M USD +2.95%
Deferred Tax Assets, Operating Loss Carryforwards 133M USD +25%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 400K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 12.9M USD +2.95%
Additional Paid in Capital 1.68B USD +2.32%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 5.02M USD -0.06%
Deferred Tax Assets, Net of Valuation Allowance 14.9M USD -10.2%
Share-based Payment Arrangement, Expense 36.4M USD -44.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%